Goldline is a drug used to treat alimentary obesity.
Release form and composition
Goldline is released in the form of hard gelatin capsules, which are filled with white powder inside, in blisters of 10 pieces. The body of the capsules is yellow, the cap is blue.
Each of them contains 10 mg of sibutramine hydrochloride monohydrate and excipients - microcrystalline cellulose, lactose, magnesium stearate and colloidal silicon dioxide.
The body of the capsules consists of gelatin, titanium dioxide, sodium lauryl sulfate, the dye quinoline yellow, and the sunset sun yellow. The composition of the cap includes the dye diamond blue and acid fuchsin, sodium lauryl sulfate, gelatin and titanium dioxide.
Goldline hard gelatin capsules are also produced, with a blue lid and a white body, which are filled with white powder inside, in blisters of 10 pcs.
The composition of one capsule includes 15 mg of sibutramine hydrochloride monohydrate and such excipients as:
- Magnesium stearate;
- Microcrystalline cellulose;
- Colloidal silicon dioxide;
The capsule body contains gelatin, titanium dioxide, and sodium lauryl sulfate. The cap of the capsules consists of sodium lauryl sulfate, acid fuchsin and brilliant blue dye, gelatin and titanium dioxide.
Indications for use
The instructions to Goldline indicated that the drug is prescribed to patients with alimentary obesity with a BMI (body mass index) greater than 30 kg per m2. Also, the drug is prescribed for alimentary obesity with a BMI greater than 27 kg / m2, combined with dyslipoproteinemia or type 2 diabetes.
The drug is not prescribed to children under 18 and patients over 65 years of age. The use of Goldline is contraindicated in case of hypersensitivity to the components included in its composition, as well as in the following cases:
- Pregnancy and during the breastfeeding period;
- Syndrome Gilles de la Tourette;
- The presence of organic causes of obesity;
- Severe eating disorders;
- Mental illness;
- The use of other drugs that have an effect on the central nervous system;
- Coronary heart disease;
- Severe liver or kidney problems;
- Cerebrovascular diseases;
- Simultaneous administration of MAO inhibitors or their use within 14 days before the appointment of Goldline;
- The use of other centrally acting drugs for weight loss;
- Uncontrolled arterial hypertension;
- Established alcohol, drug or pharmacological dependence;
- Benign prostatic hyperplasia;
- Congenital heart defects;
- Closed angle glaucoma.
With care, Goldline is prescribed to patients with arterial hypertension, chronic circulatory failure, arrhythmias, history of motor and verbal tics, coronary artery disease and cholelithiasis.
Dosing and Administration
Capsules are inside, regardless of the meal, once a day in the morning, without chewing and drinking a glass of water. Goldline dosage is determined individually, depending on the clinical efficacy and tolerability of the drug.
The recommended initial dose is 10 mg, with poor tolerance - 5 mg. If during 28 days from the start of therapy a weight reduction of 5% or more is not achieved, the dose is increased to 15 mg per day.
For patients who for 90 days cannot reduce weight by 5% from the initial level, the duration of therapy should not exceed 3 months.
In cases where, after losing weight during the drug treatment period, the patient regains 3 kg or more, Goldline is required to be canceled.
The instructions to Goldline stated that the drug may cause side effects from some body systems, namely:
- Headache, anxiety, insomnia, dizziness and paresthesias (central nervous system);
- Palpitations, symptoms of vazolidation, tachycardia, exacerbation of hemorrhoids and high blood pressure (cardiovascular system);
- Loss of appetite, dry mouth, nausea, constipation and change in taste (digestive system).
In rare cases, Goldline causes excessive sweating, swelling, itchy skin, a paradoxical increase in appetite, depression, thirst, drowsiness, rhinitis, back pain, Schönlein-Henoch purpura and
- Abdominal pain;
- Emotional lability;
- Flu-like syndrome;
The use of Goldline is permissible only in those cases when all non-drug measures aimed at weight loss did not bring significant results (weight loss in 3 months was less than 5 kg).
Reception of the drug should be carried out in the framework of complex therapy under the supervision of a physician with experience in the treatment of obesity. It is important to combine taking the drug with a healthy lifestyle, including both a change in diet and physical activity.
Patients during the use of Goldline should change their habits and way of life in such a way that the achieved results are maintained even after discontinuation of the drug. They need to realize that failure to comply with these requirements leads to a repeated weight gain, because of which they will again have to contact a specialist.
The duration of drug therapy should not exceed 2 years.
Synonyms of the drug are Meridia, Slimia and Lindax. Goldline’s analogues include Fepranon and Reduxine.
Terms and conditions of storage
In accordance with the instructions, Goldline should be stored in a dark, dry and out of reach of children, at a temperature not exceeding 25 ° C.
From pharmacies, the drug is released on prescription. The shelf life of capsules, subject to the recommendations of the manufacturer, is two years. Goldline cannot be used after the expiration date.